

*The APOB insertion/deletion polymorphism (rs17240441) influences postprandial lipaemia in healthy adults*

Article

Published Version

Creative Commons: Attribution 3.0 (CC-BY)

Open Acces

Vimalleswaran, K. S., Minihane, A. M., Li, Y., Gill, R., Lovegrove, J. A. ORCID: <https://orcid.org/0000-0001-7633-9455>, Williams, C. M. and Jackson, K. G. ORCID: <https://orcid.org/0000-0002-0070-3203> (2015) The APOB insertion/deletion polymorphism (rs17240441) influences postprandial lipaemia in healthy adults. *Nutrition & Metabolism*, 12 (1). 7. ISSN 1743-7075 doi: <https://doi.org/10.1186/s12986-015-0002-9> Available at <https://centaur.reading.ac.uk/39774/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1186/s12986-015-0002-9>

Publisher: BioMed Central Ltd

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

**CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

**BRIEF COMMUNICATION**

**Open Access**

# The *APOB* insertion/deletion polymorphism (rs17240441) influences postprandial lipaemia in healthy adults

Karani Santhanakrishnan Vimaleswaran<sup>1,2\*</sup>, Anne M Minihane<sup>1,3</sup>, Yue Li<sup>1,2</sup>, Rosalyn Gill<sup>4</sup>, Julie A Lovegrove<sup>1,2</sup>, Christine M Williams<sup>2</sup> and Kim G Jackson<sup>1,2</sup>

## Abstract

**Background:** Apolipoprotein (apo)B is the structural apoprotein of intestinally- and liver- derived lipoproteins and plays an important role in the transport of triacylglycerol (TAG) and cholesterol. Previous studies have examined the association between the *APOB* insertion/deletion (ins/del) polymorphism (rs17240441) and postprandial lipaemia in response to a single meal; however the findings have been inconsistent with studies often underpowered to detect genotype-lipaemia associations, focused mainly on men, or with limited postprandial characterisation of participants. In the present study, using a novel sequential test meal protocol which more closely mimics habitual eating patterns, we investigated the impact of *APOB* ins/del polymorphism on postprandial TAG, non-esterified fatty acids, glucose and insulin levels in healthy adults.

**Findings:** Healthy participants (n = 147) consumed a standard test breakfast (0 min; 49 g fat) and lunch (330 min; 29 g fat), with blood samples collected before (fasting) and on 11 subsequent occasions until 480 min after the test breakfast. The ins/ins homozygotes had higher fasting total cholesterol, LDL-cholesterol, TAG, insulin and HOMA-IR and lower HDL-cholesterol than del/del homozygotes (P < 0.017). A higher area under the time response curve (AUC) was evident for the postprandial TAG (P < 0.001) and insulin (P = 0.032) responses in the ins/ins homozygotes relative to the del/del homozygotes, where the genotype explained 35% and 7% of the variation in the TAG and insulin AUCs, respectively.

**Conclusions:** In summary, our findings indicate that the *APOB* ins/del polymorphism is likely to be an important genetic determinant of the large inter-individual variability in the postprandial TAG and insulin responses to dietary fat intake.

**Keywords:** *APOB* gene, Signal peptide polymorphism, Insertion/deletion polymorphism, Postprandial study, Sequential test meals, Triacylglycerol

## Findings

### Introduction

Apolipoprotein (Apo)B is the structural apoprotein of intestinally- (e.g. chylomicrons, apoB-48) and liver- (e.g. very low density lipoprotein (VLDL), apoB-100) derived lipoproteins and plays an important role in the transport of triacylglycerol (TAG) and cholesterol [1]. The *APOB* insertion/

deletion (ins/del) polymorphism (rs17240441), which produces a difference of three amino acids in the signal peptide, has been associated with fasting total cholesterol (TC) [2,3], TAG [4,5], high density lipoprotein-cholesterol (HDL-C) [2] and low density lipoprotein-cholesterol (LDL-C) [2,3] concentrations, along with cardiovascular disease-related outcomes [6-11]. In addition, the effect of this polymorphism on lipid metabolism appears to be modulated by dietary fat and cholesterol intakes [4,12].

Non-fasting (postprandial) TAG is now recognised as a highly significant and arguably independent risk factor for cardiovascular disease [13-16]. However, the postprandial

\* Correspondence: v.karani@reading.ac.uk

<sup>1</sup>Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading RG6 6AP, UK

<sup>2</sup>Institute for Cardiovascular and Metabolic Research (ICMR), University of Reading, Reading, UK

Full list of author information is available at the end of the article

lipaemic response is highly heterogeneous, with inter-individual variability in response to meal ingestion shown to be modulated by environmental and genetic factors [13,14,17]. Previous studies have examined the association between the *APOB* ins/del polymorphism and postprandial lipaemia in response to a single meal [8,9,18,19] but findings have been inconsistent with studies often under-powered to examine genotype-lipaemia associations, focussed mainly on men, or with limited (both in terms of time-points and measurements) postprandial characterisation of participants. Hence, in the present study, using a novel sequential test meal protocol which more closely mimics habitual eating patterns, we examined the effect of the *APOB* ins/del polymorphism on postprandial TAG, non-esterified fatty acids (NEFA), glucose and insulin levels in healthy adults.

## Methods

### Study participants

The study was performed using postprandial data from 147 healthy participants who underwent the same sequential test meal protocol and similar inclusion/exclusion criteria, at the University of Reading between 1997 and 2007, as previously described [20]. Briefly, healthy men and women aged 20-70 years, with a body mass index (BMI) between 19-32 kg/m<sup>2</sup>, fasting TAG levels ≤4 mmol/l and total cholesterol ≤8 mmol/l were recruited (Table 1). The studies were approved by the University of Reading Research Ethics Committee and the West Berkshire Health Authority Ethics Committee, and written informed consent was obtained from all participants.

**Table 1 Characteristics of the men and women in the postprandial dataset (n = 147)**

|                          | Men         | Women       | P value |
|--------------------------|-------------|-------------|---------|
| Age (y)                  | 54 ± 10     | 54 ± 11     | 0.868   |
| BMI (kg/m <sup>2</sup> ) | 27.6 ± 3.1  | 25.6 ± 3.5  | 0.002   |
| TC (mmol/l)              | 6.15 ± 0.94 | 5.99 ± 0.97 | 0.390   |
| TAG (mmol/l)             | 2.05 ± 0.83 | 1.39 ± 0.50 | <0.001  |
| HDL-C (mmol/l)           | 1.10 ± 0.26 | 1.41 ± 0.27 | <0.001  |
| LDL-C (mmol/l)           | 4.12 ± 0.91 | 3.95 ± 0.81 | 0.313   |
| NEFA (μmol/l)            | 490 ± 185   | 539 ± 202   | 0.288   |
| Glucose (mmol/l)         | 5.32 ± 0.67 | 5.14 ± 0.48 | 0.109   |
| Insulin (pmol/l)         | 54.0 ± 32.0 | 39.2 ± 26.3 | 0.011   |
| HOMA-IR                  | 2.2 ± 1.5   | 1.5 ± 1.1   | 0.010   |

Values represent mean ± SD for n = 112 men and n = 35 women.

The data represents n = 85 men and n = 34 women for insulin and HOMA-IR, and n = 109 men and n = 33 women for NEFA.

Abbreviations: BMI body mass index, NEFA non-esterified fatty acids, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, TAG triacylglycerol, TC total cholesterol.

### Postprandial protocol

Details of the postprandial protocol have been described previously [20]. Briefly, study participants were asked to refrain from alcohol or organised exercise regimens on the previous day and were provided with a relatively low fat (<10 g fat) evening meal to standardise short-term fat intake. After a 12 h overnight fast, a blood sample was taken. Following a standard test breakfast (0 min; 3.9 MJ energy, 111 g carbohydrate, 19 g protein and 49 g fat) and lunch (330 min; 2.3 MJ energy, 63 g carbohydrate, 15 g protein and 29 g fat), blood samples were taken at 30–60 min intervals until 480 min after the test breakfast.

### Biochemical analysis

Plasma lipids and glucose were analysed with an automated analyser (Instrumentation Laboratory (UK) Ltd, Warrington, UK) using enzyme-based kits supplied by Instrumentation Laboratory and Alpha Laboratories (Eastleigh, UK). In the fasting sample, HDL-C was measured in the supernatant following precipitation of the apoB-containing lipoproteins with a dextran-manganese chloride reagent. LDL-C was calculated using the Friedewald formula. Insulin was measured by ELISA (Dako Ltd, High Wycombe, UK). The homeostasis assessment model of insulin resistance (HOMA-IR) was calculated using the formula: [fasting insulin (pmol/l) × fasting glucose (mmol/l)]/135. All samples for each individual were analysed within a single batch and the inter-assay coefficient of variation for the assays were less than 5%.

### Genotyping

DNA was isolated from the buffy coat layer as previously described [20]. The ins/del polymorphism was detected using a PCR-agarose gel electrophoresis as described previously [4]. The genotype distribution of this polymorphism was in concordance with Hardy-Weinberg equilibrium (P = 0.87).

### Statistical analysis

Statistical analysis was carried out using the STATA version 13. The data were checked for normality prior to statistical analysis and transformed where necessary. The data in Table 1 which could not be normalised (age, BMI, fasting total cholesterol, glucose, insulin, NEFA and HOMA-IR) were analysed using a Mann-Whitney test and an Independent-Samples *t* test for those with a normal distribution. Postprandial summary measures for the TAG, glucose and insulin responses included area under the curve (AUC, 0-480 min) and incremental AUC (IAUC, 0-480 min). Since postprandial NEFA concentrations show an initial drop after the breakfast meal, NEFA AUC and IAUC responses were calculated from the minimum concentration until the end of the postprandial investigation (120-480 min). Linear regression

analysis (adjusting for age, gender and BMI) was used to determine the impact of genotype on the fasting metabolites and postprandial summary measures (AUC and IAUC). The interactions of the polymorphism with age, gender and BMI were tested by including the interaction term in the linear regression model.

## Results

Table 1 shows the characteristics of the men and women in the postprandial cohort. Men had significantly higher BMI, fasting TAG, insulin and HOMA-IR, and lower HDL-C than women ( $P \leq 0.010$ ).

Compared with the del/del homozygotes, insertion allele carriers had higher fasting TC (versus ins/del  $P = 0.017$ ; ins/ins,  $P = 0.013$ ), LDL-C (versus ins/del  $P = 0.011$ ; ins/ins,  $P = 0.017$ ), TAG (versus ins/del,  $P = 0.049$ ; ins/ins,  $P = 0.006$ ), and lower HDL-C (versus ins/del,  $P = 0.004$ ; ins/ins,  $P = 0.003$ ). Ins/Ins homozygotes had higher fasting insulin and HOMA-IR than the del/del ( $P = 0.001$ ) and ins/del ( $P = 0.012$ ) groups (Table 2). There was no association between the polymorphism and fasting NEFA or glucose concentrations ( $P > 0.079$ ).

There was a significant effect of the *APOB* polymorphism on the postprandial TAG response (Figure 1A), with

**Table 2 Fasting metabolites and postprandial measures according to the *APOB* insertion/deletion polymorphism in the study participants**

| Participant characteristics             | Del/Del<br>(n = 52)        | Ins/Del<br>(n = 70)        | Ins/Ins<br>(n = 25)         | Overall<br>P value* |
|---|----------------------------|----------------------------|-----------------------------|---------------------|
| Age (y)                                 | 52 ± 2                     | 56 ± 1                     | 53 ± 2                      | 0.176               |
| Gender (men/women)                      | 36/16                      | 53/17                      | 23/2                        | 0.090               |
| Body mass index (kg/m <sup>2</sup> )    | 26.6 ± 0.4                 | 27.2 ± 0.4                 | 27.9 ± 0.8                  | 0.184**             |
| <b>Fasting metabolites</b>              |                            |                            |                             |                     |
| Total cholesterol (mmol/l)              | 5.77 ± 0.12 <sup>A</sup>   | 6.26 ± 0.11 <sup>B</sup>   | 6.43 ± 0.21 <sup>B</sup>    | 0.004               |
| Triacylglycerol (mmol/l)                | 1.62 ± 0.09 <sup>A</sup>   | 1.96 ± 0.10 <sup>B</sup>   | 2.25 ± 0.14 <sup>B</sup>    | 0.007               |
| LDL-C (mmol/l)                          | 3.75 ± 0.10 <sup>A</sup>   | 4.24 ± 0.11 <sup>B</sup>   | 4.32 ± 0.19 <sup>B</sup>    | 0.007               |
| HDL-C (mmol/l)                          | 1.29 ± 0.04 <sup>A</sup>   | 1.13 ± 0.03 <sup>B</sup>   | 1.04 ± 0.04 <sup>B</sup>    | 0.002               |
| NEFA (μmol/l)                           | 525.4 ± 31.5               | 503.5 ± 22.2               | 448.0 ± 22.1                | 0.079               |
| Glucose (mmol/l)                        | 5.23 ± 0.08                | 5.28 ± 0.07                | 5.39 ± 0.15                 | 0.798               |
| Insulin <sup>∞</sup> (pmol/l)           | 43.9 ± 3.37 <sup>A</sup>   | 48.9 ± 4.08 <sup>A</sup>   | 74.9 ± 12.3 <sup>B</sup>    | 0.007               |
| HOMA-IR                                 | 1.73 ± 0.14 <sup>A</sup>   | 1.99 ± 0.18 <sup>A</sup>   | 3.15 ± 0.57 <sup>B</sup>    | 0.004               |
| <b>Postprandial summary measures</b>    |                            |                            |                             |                     |
| Triacylglycerol (mmol/l × 480 min)      |                            |                            |                             |                     |
| AUC                                     | 1024.3 ± 52.5 <sup>A</sup> | 1268.9 ± 61.3 <sup>B</sup> | 1841.6 ± 135.4 <sup>C</sup> | <0.001              |
| IAUC                                    | 273.3 ± 22.4 <sup>A</sup>  | 326.0 ± 25.4 <sup>A</sup>  | 511.6 ± 58.3 <sup>B</sup>   | <0.001              |
| NEFA (mmol/l × 300 min) <sup>‡</sup>    |                            |                            |                             |                     |
| AUC                                     | 160.0 ± 5.8                | 153.4 ± 6.2                | 149.8 ± 6.3                 | 0.153               |
| IAUC                                    | 94.8 ± 7.3                 | 101.7 ± 3.9                | 91.3 ± 5.2                  | 0.539               |
| Glucose (mmol/l × 480 min)              |                            |                            |                             |                     |
| AUC                                     | 2979.1 ± 48.9              | 2946.9 ± 83.9              | 3184.9 ± 62.4               | 0.527               |
| IAUC                                    | 489.9 ± 43.9               | 557.7 ± 31.4               | 533.3 ± 34.7                | 0.306               |
| Insulin <sup>∞</sup> (nmol/l × 480 min) |                            |                            |                             |                     |
| AUC                                     | 25.7 ± 8.6 <sup>A</sup>    | 24.8 ± 6.1 <sup>A</sup>    | 81.5 ± 23.0 <sup>B</sup>    | 0.036               |
| IAUC                                    | 113.2 ± 21.5               | 91.2 ± 9.8                 | 172.8 ± 25.4                | 0.108               |

Values represent mean ± SEM. Abbreviations: AUC area under the curve, HDL-C high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, IAUC incremental area under the curve, LDL-C low density lipoprotein cholesterol, NEFA non-esterified fatty acids.


Means with different superscript capital letters (A,B,C) denote significant differences between the Del/Del, Del/Ins and Ins/Ins genotypes ( $P < 0.05$ ; see text for exact P values).

<sup>∞</sup>Only 119 individuals had data for fasting insulin (n = 52 for del/del, n = 53 for del/ins and n = 14 for ins/ins) and n = 35 with postprandial insulin concentrations (n = 10 for del/del, n = 15 for del/ins and n = 10 for ins/ins).

\*Adjusted for age, gender and BMI.

\*\*Adjusted for age and gender.

<sup>‡</sup>AUC and IAUC for the NEFA response are calculated from the time of suppression (120 min) to the end of the postprandial period (480 min).



**Figure 1** Effect of *APOB* ins/del polymorphism on postprandial triacylglycerol (TAG) and insulin response. **A.** Mean (SEM) for the postprandial TAG response in the *APOB* del/del (n = 52, open circles), del/ins (n = 70, open squares) and ins/ins (n = 25, open triangles) genotype groups after consumption of a test breakfast (49 g fat) at 0 min and a test lunch (29 g fat) at 330 min. There was a 44% and 31% higher TAG area under the curve (AUC) (del/del vs ins/del,  $P = 0.010$ ; del/del vs ins/ins,  $P < 0.001$ ; ins/del vs ins/ins,  $P < 0.001$ ) in the ins/ins than del/del homozygotes and ins/del heterozygotes, respectively. **B.** Mean (SEM) for the AUC for the postprandial TAG response in men and women in the *APOB* del/del (white bars; n = 36 men/n = 16 women), del/ins (black bars; n = 51 men/n = 17 women) and ins/ins (dotted bars; n = 23 men/n = 2 women) genotype groups. There was a significant effect of genotype on the TAG AUC in men only ( $P = 0.043$ , del/del vs ins/del;  $P < 0.001$ , ins/ins vs both del/del and ins/del) whereas differences between genotypes were not evident in women ( $P > 0.501$ ). **C.** Mean (SEM) for the postprandial insulin response in the *APOB* del/del (n = 10, open circles), del/ins (n = 15, open squares) and ins/ins (n = 10, open triangles) genotype groups after consumption of a test breakfast (49 g fat) at 0 min and a test lunch (29 g fat) at 330 min. There was a 69% higher AUC in the ins/ins than ins/del ( $P = 0.004$ ) and del/del ( $P = 0.032$ ) groups.

a 44% and 31% higher TAG AUC (del/del vs ins/del,  $P = 0.010$ ; del/del vs ins/ins,  $P < 0.001$ ; ins/del vs ins/ins,  $P < 0.001$ ) and 47% and 36% higher IAUC (del/del vs ins/ins,  $P < 0.001$ ; ins/del vs ins/ins,  $P = 0.001$ ) in the ins/ins than del/del homozygotes and ins/del heterozygotes, respectively (Table 2). The polymorphism explained 35% and 20% of the variation in the TAG AUC and IAUC, respectively. The penetrance of genotype on TAG AUC and IAUC did not vary by age ( $P > 0.94$ ) or BMI ( $P > 0.10$ ); however, there was a significant interaction with gender ( $P < 0.04$ ), with an impact of genotype observed only in men. Even after excluding the ins/ins individuals (n = 25), given the gender imbalance in this group (Table 2), a gender-specific effect of genotype on postprandial TAG AUC was still observed (men,  $P = 0.01$ ; women,  $P = 0.24$ ) (Figure 1B).

For the postprandial insulin response (Figure 1C), a significant effect of the polymorphism on AUC but not IAUC ( $P = 0.108$ ) was observed, with a 69% higher AUC in the ins/ins than ins/del ( $P = 0.004$ ) and del/del ( $P = 0.032$ ) groups. The genotype explained 7% of the variation in AUC. Significant genotype effects were not observed for the summary measures of the postprandial glucose and NEFA responses.

## Discussion

Our data provides evidence of a significant role of the *APOB* ins/del polymorphism in determining postprandial TAG and insulin responses to sequential meal ingestion. Furthermore, we have shown an impact of this polymorphism on the fasting lipid profile, insulin and HOMA-IR, a surrogate measure of insulin resistance.

The ins/del polymorphism arises due to an insertion or a deletion of 9 base pairs that produces apoB signal peptides of 27 and 24 amino acids in length, respectively [21]. A less effective translocation of newly synthesised apoB across the endoplasmic reticulum membrane has been reported with the shorter signal peptide, suggesting this polymorphism may impact on TAG-rich lipoprotein (TRL, CM and VLDL) production. As with previous findings [8,9,19], insertion allele carriers showed higher fasting and postprandial TAG concentrations which was associated with decreased HDL-C levels. Intriguingly, the dose response for the impact of the insertion allele on TAG-AUC (ins/ins > ins/del > del/del) was only evident in men, a phenomenon we have previously observed in our cohort for the *LEPR* [20] and *APOA5* [22] genotypes. Expression of the biochemical phenotype of this *APOB* polymorphism has been proposed to be dependent on the population studied [19]. Irrespective of genotype, men had higher BMI, fasting TAG, insulin and HOMA-IR, and lower HDL-C than women (Table 1), which may have influenced the genotype-gender relationships with postprandial TAG handling. However, the small proportion of women in our dataset (n = 35/147) limits definite conclusions that the impact of genotype is only evident in men.

Dietary fat quantity has been reported to influence the effect of this genotype on TAG levels, with a greater association observed when participants consumed a high-fat than low-fat diet. Xu et al. [4] proposed the overall reduction in TRL synthesis during the low-fat diet to be responsible for the loss of the genotype effect on the intracellular handling of apoB. Furthermore, the TRL-TAG content, but not particle number (apoB concentration), was different between the ins/del groups during the high-fat diet indicating this polymorphism may also influence TRL composition. The reduced ability of the ins/ins homozygotes to handle dietary TAG after meal ingestion in the present study was associated with a higher fasting HOMA-IR and postprandial insulin AUC. In the absence of any known direct effect of apoB on insulin production or cellular action, it is likely that the higher insulin levels are in response to higher postprandial TAG. The associated loss of insulin sensitivity would likely impact on various stages of TRL metabolism. However, we did not determine apoB in the present study and hence it is difficult to discriminate between the potential contributions of increased TRL production versus impaired TAG clearance (both highly insulin dependent processes), to the higher TAG response in the insertion allele carriers.

In summary, our findings indicate the *APOB* ins/del polymorphism is likely to be an important determinant of the inter-individual variability in the postprandial TAG and insulin responses to dietary fat intake. However, we were unable to replicate these findings due to

the lack of access to another postprandial cohort with data on this polymorphism. Hence, replication is highly warranted and, to determine in particular whether the penetrance of genotype on the TAG response is gender-specific. Further work is required to investigate the impact of the *APOB* ins/del polymorphism on TRL metabolism, and coronary heart disease risk.

#### Abbreviations

ApoB: Apolipoprotein B; HDL-C: High density lipoprotein-cholesterol; HOMA-IR: Homeostasis assessment model of insulin resistance; LDL-C: Low density lipoprotein-cholesterol; NEFA: Non-esterified fatty acids; TAG: Triacylglycerol; TC: Total cholesterol.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

KSV performed the statistical analysis and drafted the manuscript. YL contributed to the data analysis. CMW, JAL, AMM and KGJ designed the postprandial studies, with RG providing input into the genetic focus of the work. All authors contributed to and approved the final version of the manuscript.

#### Acknowledgements

The authors wish to thank Mrs Jan Luff for her help with volunteer recruitment and Professor Philippa Talmud for her help with the genotyping.

#### Funding

The baseline data used for the genotyping analysis was derived from postprandial studies supported by grants from the BBSRC (Reference no. D18350), DEFRA, Unilever Research, Roche Vitamins Ltd, the Agri-Food LINK programme, Raffinerie Tirlemontoise (ORAFIT) and Nestlé between 1996 and 2000.

#### Author details

<sup>1</sup>Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading RG6 6AP, UK. <sup>2</sup>Institute for Cardiovascular and Metabolic Research (ICMR), University of Reading, Reading, UK. <sup>3</sup>Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, UK. <sup>4</sup>Boston Heart Diagnostics, Framingham, MA 01702, USA.

Received: 20 October 2014 Accepted: 3 February 2015

Published online: 08 March 2015

#### References

- Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. *Sci Am*. 1984;251:58–66.
- Kallel A, Feki M, Elasmı M, Souissi M, Sanhaji H, Omar S, et al. Apolipoprotein B signal peptide polymorphism: distribution and influence on lipid parameters in Tunisian population. *Physiol Res/Academia Scientiarum Bohemoslovaca*. 2007;56:411–7.
- Hubacek JA, Waterworth DM, Poledne R, Pitha J, Skodova Z, Humphries SE, et al. Genetic determination of plasma lipids and insulin in the Czech population. *Clin Biochem*. 2001;34:113–8.
- Xu CF, Tikkanen MJ, Huttunen JK, Pietinen P, Butler R, Humphries S, et al. Apolipoprotein B signal peptide insertion/deletion polymorphism is associated with Ag epitopes and involved in the determination of serum triglyceride levels. *J Lipid Res*. 1990;31:1255–61.
- Boekholdt SM, Peters RJ, Fountoulaki K, Kastelein JJ, Sijbrands EJ. Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. *Hum Genet*. 2003;113:417–25.
- Gardemann A, Ohly D, Fink M, Katz N, Tillmanns H, Hehrlein FW, et al. Association of the insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction. *Atherosclerosis*. 1998;141:167–75.

7. De Padua Mansur A, Annicchino-Bizzacchi J, Favarato D, Avakian SD, Machado Cesar LA, Franchini Ramires JA. Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease. *Am J Cardiol*. 2000;85:1089–93.
8. Regis-Bailly A, Fournier B, Steinmetz J, Gueguen R, Siest G, Visvikis S. Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. *Atherosclerosis*. 1995;118:23–34.
9. Byrne CD, Wareham NJ, Mistry PK, Phillips DI, Martensz ND, Halsall D, et al. The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide. *Atherosclerosis*. 1996;127:35–42.
10. Hixson JE, McMahan CA, McGill Jr HC, Strong JP. Apo B insertion/deletion polymorphisms are associated with atherosclerosis in young black but not young white males: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Arterioscler Thromb*. 1992;12:1023–9.
11. Lamia R, Asma O, Slim K, Jihene R, Imen B, Ibtihel BH, et al. Association of four apolipoprotein B polymorphisms with lipid profile and stenosis in Tunisian coronary patients. *J Genet*. 2012;91:75–9.
12. Boerwinkle E, Brown SA, Rohrbach K, Gotto Jr AM, Patsch W. Role of apolipoprotein E and B gene variation in determining response of lipid, lipoprotein, and apolipoprotein levels to increased dietary cholesterol. *Am J Hum Genet*. 1991;49:1145–54.
13. Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. *Atherosclerosis*. 2012;220:22–33.
14. Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease. *Curr Atheroscler Rep*. 2003;5:437–44.
15. Perez-Martinez P, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Update on genetics of postprandial lipemia. *Atheroscler Suppl*. 2010;11:39–43.
16. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA*. 2007;298:309–16.
17. Lopez-Miranda J, Marin C. Dietary, physiological, and genetic impacts on postprandial lipid metabolism. In: Montmayeur JP, le Coutre J, editors. *Fat detection: taste, texture, and post ingestive effects*. Boca Raton (FL): Frontiers in Neuroscience; 2010.
18. Syvanne M, Talmud PJ, Humphries SE, Fisher RM, Rosseneu M, Hilden H, et al. Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterol. *J Lipid Res*. 1997;38:1463–72.
19. Halsall DJ, Martensz ND, Luan J, Maison P, Wareham NJ, Hales CN, et al. A common apolipoprotein B signal peptide polymorphism modifies the relation between plasma non-esterified fatty acids and triglyceride concentration in men. *Atherosclerosis*. 2000;152:9–17.
20. Jackson KG, Delgado-Lista J, Gill R, Lovegrove JA, Williams CM, Lopez-Miranda J, et al. The leptin receptor Gln223Arg polymorphism (rs1137101) mediates the postprandial lipaemic response, but only in males. *Atherosclerosis*. 2012;225:135–41.
21. Visvikis S, Chan L, Siest G, Drouin P, Boerwinkle E. An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. *Hum Genet*. 1990;84:373–5.
22. Olano-Martin E, Abraham EC, Gill-Garrison R, Valdes AM, Grimaldi K, Tang F, et al. Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender. *J Lipid Res*. 2008;49:945–53.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

